Predictors of Antiestrogen Recommendation in Women With Estrogen Receptor–Positive Ductal Carcinoma In Situ

Restricted access

Background: Antiestrogen (anti-e) use in estrogen receptor–positive (ER+) ductal carcinoma in situ (DCIS) has been shown to reduce the incidence of noninvasive and invasive breast cancer. Few studies have evaluated factors associated with anti-e recommendation in ER+ DCIS. Methods: The California Cancer Registry was queried for female patients diagnosed with ER+ DCIS and treated with lumpectomy or unilateral mastectomy from 2004 to 2011. Patient demographics, comorbidities, and clinical characteristics were analyzed for association with anti-e recommendation. Results: Of 5,527 patients identified, 76.4% patients underwent lumpectomy and 23.6% underwent unilateral mastectomy. Of the total cohort, 31.6% patients were recommended anti-e therapy, 60.4% were not, and the remaining 8.0% were recommended anti-e, but administration was not documented. Performance of lumpectomy predicted anti-e use compared with mastectomy (odds ratio [OR], 2.08; 95% CI, 1.77–2.43). Asian/Pacific Islanders were more often recommended anti-e therapy when compared with whites (OR, 1.28; 95% CI, 1.10–1.49). Patients younger than 70 years were more often recommended anti-e (age, 18–49 years: OR, 1.38; CI, 1.12–1.71; and age, 50–69 years: OR, 1.43; CI, 1.20–1.71). Conclusions: Despite current guidelines to consider the use of anti-e therapy, recommendation of anti-e after surgical treatment of DCIS is low, having been recommended to 40% of patients, and used by fewer than one-third. Significant predictors include lumpectomy compared with unilateral mastectomy, Asian/Pacific Islander race, younger age, and number of comorbidities. Further work is merited to understand patterns of anti-e therapy recommendation by providers in patients with DCIS.

Correspondence: Courtney Vito, MD, Department of Oncologic Surgery, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010-8113. E-mail: cvito@coh.org
  • 1.

    Morrow M. Refining the use of endocrine therapy for ductal carcinoma in situ. J Clin Oncol 2012;30:12491251.

  • 2.

    Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast. 5th ed. Philadelphia, PA: Wolters Kluwer Health; 2014.

  • 3.

    Lakhani SR, Ellis IO, Schnitt SJ. World Health Organization Classification of Tumours of the Breast. 4th ed. Lyons, France: International Agency for Research on Cancer; 2012.

    • Search Google Scholar
    • Export Citation
  • 4.

    Allred DC, Anderson SJ, Paik S. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen-receptor positive ductal carcinoma in situ: a study based on NSABP Protocol B-24. J Clin Oncol 2012;30:12681273.

    • Search Google Scholar
    • Export Citation
  • 5.

    Fisher B, Dignam J, Wolmark. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:19932000.

    • Search Google Scholar
    • Export Citation
  • 6.

    Carlson RW, Anderson BO, Bensinger W. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2010. Accessed March 20, 2015. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 7.

    Goss PE, Ingle JN, Ales-Martinez JE. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011;364:23812391.

  • 8.

    Margolese RG, Cecchini RS, Julian TB. Primary results, NRG Oncology/NSABP B-35: a clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIs undergoing lumpectomy plus radiation [abstract]. J Clin Oncol 2015;33(Suppl):Abstract LBA 500.

    • Search Google Scholar
    • Export Citation
  • 9.

    Cuncins-Hearn A, Boult M, Babidge W. National Breast Cancer Audit: ductal carcinoma in situ management in Australia and New Zealand. ANZ J Surg 2007;77:6468.

    • Search Google Scholar
    • Export Citation
  • 10.

    Yen TW, Hunt KK, Mirza NQ. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 2004;100:942949.

    • Search Google Scholar
    • Export Citation
  • 11.

    Nakhlis F, Lazarus L, Hou N. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b invasive carcinoma. J Am Coll Surg 2005;201:688694.

    • Search Google Scholar
    • Export Citation
  • 12.

    Zujewski JA, Harlan LC, Morrell DM. Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat 2011;127:251257.

    • Search Google Scholar
    • Export Citation
  • 13.

    NCCN Member Institutions. Available at: https://www.nccn.org/members/network.aspx. Accessed May 28, 2015.

  • 14.

    NCI-Designated Cancer Centers. Available at: cancer.gov/research/nci-role/cancer-centers. Accessed May 28, 2015.

  • 15.

    California Cancer Registry. Available at: http://ccrcal.org. Accessed December 21, 2014.

  • 16.

    Rhoads KF, Patel MI, Ma Y, Schmidt LA. How do integrated health care systems address racial and ethnic disparities in colon cancer? J Clin Oncol 2015;8:854860.

    • Search Google Scholar
    • Export Citation
  • 17.

    North American Association of Central Cancer Registries. US Registries Certified in 2013 for 2010 Incidence Data. Available at: http://www.naaccr.org/Certification/USCert2010.aspx. Accessed May 24, 2015.

    • Search Google Scholar
    • Export Citation
  • 18.

    Yang J, Schupp CW, Harrati A. Developing an area-based socioeconomic measure from American Community Survey data. Fremont, CA: Cancer Prevention Institute of California; 2014. Available at: http://www.cpic.org/files/PDF/Research_Files/Reports/CPIC_ACS_SES_Index_Documentation_3-10-2014.pdf. Accessed July 25, 2016.

    • Search Google Scholar
    • Export Citation
  • 19.

    Yost K, Perkins C, Cohen R. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 2001;12:703711.

    • Search Google Scholar
    • Export Citation
  • 20.

    Office of Statewide Health Planning and Development. Available at: http://www.oshpd.ca.gov/AboutUs.html. Accessed March 9, 2015.

  • 21.

    California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals. Available at: http://ccrcal.org/DSQC_Pubs/V1_2013_Online_Manual/index.htm. Accessed July 25, 2015.

    • Search Google Scholar
    • Export Citation
  • 22.

    Gradishar WJ, Anderson BO, Balassanian R. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2015. Accessed March 20, 2015. To view the most recent version of these guidelines, visit: http://www.nccn.org.

    • Search Google Scholar
    • Export Citation
  • 23.

    Wapnir IL, Dignam JJ, Fisher B. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NASBP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103:478488.

    • Search Google Scholar
    • Export Citation
  • 24.

    Yen TW, Kuerer HM, Ottesen RA. Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol 2007;25:32513258.

    • Search Google Scholar
    • Export Citation
  • 25.

    Rutter CE, Park HS, Killelea BK, Evans SB. Growing use of mastectomy for ductal carcinoma-in-situ of the breast among young women in the United States. Ann Surg Oncol 2015;22:23782386.

    • Search Google Scholar
    • Export Citation
  • 26.

    Lee HB, Han W. Unique features of young age breast cancer and its management. J Breast Cancer 2014;17:301307.

  • 27.

    Assi HA, Khoury KE, Dbouk H. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 2013;5(Suppl 1):S28.

  • 28.

    Shanjun L, Laxminarayan R. Are physicians' prescribing decisions sensitive to drug prices? Evidence from a free-antibiotics program. Health Econ 2015;24:158174.

    • Search Google Scholar
    • Export Citation
  • 29.

    Baine M, Sahak F, Lin C. Marital status and survival in pancreatic cancer patients: a SEER based analysis. PloS One 2011;6:E21052.

  • 30.

    Ribie C, Sargent D, Moore M. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247257.

    • Search Google Scholar
    • Export Citation
  • 31.

    Bailey SR, Saperstein A, Penner AM. Race, color, and income inequality across the Americas. Demographic Research 2014;31:735756. Available at: http://www.demographic-research.org/volumes/vol31/24/31-24.pdf. Accessed July 25, 2016.

    • Search Google Scholar
    • Export Citation
  • 32.

    Margolese RG, Cecchini RS, Julian TB. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 2016;387:849856.

    • Search Google Scholar
    • Export Citation
  • 33.

    Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010;73:156166.

    • Search Google Scholar
    • Export Citation
  • 34.

    Worni M, Akushevich I, Greenup R. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst 2015;107:djv263.

  • 35.

    Meguerditchian AN, Stewart A, Roistacher J. Claims data linked to hospital registry data enhance evaluation of the quality of care of breast cancer. J Surg Oncol 2010;101:593599.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 87 57 4
PDF Downloads 26 25 5
EPUB Downloads 0 0 0